1. Home
  2. TRVI
  3. TRVI News

Latest Trevi Therapeutics Inc. (TRVI) News on November 28, 2025

Trevi Therapeutics (TRVI): Assessing Valuation After Clinical Program Advances and Cash Runway Extension
TRVI

Simply Wall St.

13 days ago

Trevi Therapeutics (TRVI): Assessing Valuation After Clinical Program Advances and Cash Runway Extension

How Trevi Therapeutics’ (TRVI) Phase 3 Progress and Fresh Funding May Influence Investor Expectations
TRVI

Simply Wall St.

13 days ago

How Trevi Therapeutics’ (TRVI) Phase 3 Progress and Fresh Funding May Influence Investor Expectations

Trevi Therapeutics (TRVI): Assessing Valuation as RIVER Trial Data Prepares for Major Scientific Debut
TRVI

Simply Wall St.

2 months ago

Trevi Therapeutics (TRVI): Assessing Valuation as RIVER Trial Data Prepares for Major Scientific Debut

How Investors May Respond To Trevi Therapeutics (TRVI) Highlighting RIVER Trial Data at ERS 2025
TRVI

Simply Wall St.

2 months ago

How Investors May Respond To Trevi Therapeutics (TRVI) Highlighting RIVER Trial Data at ERS 2025

TRVI

MT Newswires

6 months ago

Trevi Therapeutics Closes Public Offering

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
TRVI

PR Newswire

6 months ago

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

TRVI

MT Newswires

6 months ago

Trevi Therapeutics Prices $100 Million Common Stock Offering

Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock
TRVI

PR Newswire

6 months ago

Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

TRVI

MT Newswires

6 months ago

Oppenheimer Adjusts Price Target on Trevi Therapeutics to $23 From $20, Maintains Outperform Rating

TRVI

MT Newswires

6 months ago

Trevi Therapeutics Plans $100 Million Stock Sale; Shares Sliding in After-Hours Trade

Trevi Therapeutics Announces Proposed Public Offering of Common Stock
TRVI

PR Newswire

6 months ago

Trevi Therapeutics Announces Proposed Public Offering of Common Stock

Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough
TRVI

PR Newswire

6 months ago

Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough
TRVI

PR Newswire

6 months ago

Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough

H.C. Wainwright Initiates Coverage of Trevi Therapeutics (TRVI) With Buy Rating
TRVI

Insider Monkey

6 months ago

H.C. Wainwright Initiates Coverage of Trevi Therapeutics (TRVI) With Buy Rating

Trevi Therapeutics to Participate in Upcoming June Conferences
TRVI

PR Newswire

6 months ago

Trevi Therapeutics to Participate in Upcoming June Conferences

Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough
TRVI

PR Newswire

6 months ago

Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

Wall Street Analysts See a 195.05% Upside in Trevi Therapeutics (TRVI): Can the Stock Really Move This High?
TRVI

Zacks

6 months ago

Wall Street Analysts See a 195.05% Upside in Trevi Therapeutics (TRVI): Can the Stock Really Move This High?

Trevi Therapeutics Inc (TRVI) Q1 2025 Earnings Call Highlights: Promising Trial Results and ...
TRVI

GuruFocus.com

7 months ago

Trevi Therapeutics Inc (TRVI) Q1 2025 Earnings Call Highlights: Promising Trial Results and ...

Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
TRVI

PR Newswire

7 months ago

Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025
TRVI

PR Newswire

7 months ago

Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025

Trevi Therapeutics to Participate in Upcoming April Investor Conferences
TRVI

PR Newswire

8 months ago

Trevi Therapeutics to Participate in Upcoming April Investor Conferences

Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
TRVI

GlobeNewswire

8 months ago

Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

TRVI

MT Newswires

8 months ago

B. Riley Boosts Price Target on Trevi Therapeutics to $20 From $11, Keeps Buy Rating

TRVI

Thomson Reuters StreetEvents

8 months ago

Q4 2024 Trevi Therapeutics Inc Earnings Call

Trevi Therapeutics Inc (TRVI) Q4 2024 Earnings Call Highlights: Navigating Losses and Advancing ...
TRVI

GuruFocus.com

8 months ago

Trevi Therapeutics Inc (TRVI) Q4 2024 Earnings Call Highlights: Navigating Losses and Advancing ...

Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates
TRVI

PR Newswire

8 months ago

Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates

Trevi Therapeutics, Inc.'s (NASDAQ:TRVI) large institutional owners must be happy as stock continues to impress, up 57% over the past week
TRVI

Simply Wall St.

8 months ago

Trevi Therapeutics, Inc.'s (NASDAQ:TRVI) large institutional owners must be happy as stock continues to impress, up 57% over the past week

Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025
TRVI

PR Newswire

9 months ago

Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025

TRVI Stock Soars on Meeting Primary Goal in Chronic Cough Study
TRVI

Zacks

9 months ago

TRVI Stock Soars on Meeting Primary Goal in Chronic Cough Study

TRVI

MT Newswires

9 months ago

Leerink Adjusts Price Target on Trevi Therapeutics to $11 From $7, Maintains Outperform Rating

Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps
TRVI

Benzinga

9 months ago

Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps

TRVI

MT Newswires

9 months ago

Trevi Therapeutics Says Phase 2a Haduvio Trial Shows Significant Reduction in Cough Count

Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough
TRVI

PR Newswire

9 months ago

Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough
TRVI

PR Newswire

9 months ago

Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough

Trevi Therapeutics to Participate in Upcoming March Investor Conferences
TRVI

PR Newswire

9 months ago

Trevi Therapeutics to Participate in Upcoming March Investor Conferences

Trevi Therapeutics enrols all subjects in trial of Haduvio for chronic cough in IPF
TRVI

Clinical Trials Arena

9 months ago

Trevi Therapeutics enrols all subjects in trial of Haduvio for chronic cough in IPF

Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough
TRVI

PR Newswire

9 months ago

Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

TRVI

MT Newswires

9 months ago

Oppenheimer Adjusts Trevi Therapeutics Price Target to $12 From $9, Maintains Outperform Rating

Why Trevi Therapeutics (TRVI) Is Advancing Today
TRVI

Insider Monkey

9 months ago

Why Trevi Therapeutics (TRVI) Is Advancing Today

Trevi Therapeutics to Participate in Upcoming February Investor Conferences
TRVI

PR Newswire

10 months ago

Trevi Therapeutics to Participate in Upcoming February Investor Conferences

What Makes Trevi Therapeutics (TRVI) a New Buy Stock
TRVI

Zacks

a year ago

What Makes Trevi Therapeutics (TRVI) a New Buy Stock

TRVI

MT Newswires

a year ago

B. Riley Adjusts Trevi Therapeutics' Price Target to $11 From $6, Maintains Buy Rating

Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference
TRVI

PR Newswire

a year ago

Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference

TRVI

MT Newswires

a year ago

Trevi Therapeutics Prices $50 Million Underwritten Offering

Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering
TRVI

PR Newswire

a year ago

Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering

Trevi’s chronic cough trial in IPF subjects continues without sample size change
TRVI

Clinical Trials Arena

a year ago

Trevi’s chronic cough trial in IPF subjects continues without sample size change

TRVI

MT Newswires

a year ago

Sector Update: Health Care Stocks Softer Thursday Afternoon

TRVI

MT Newswires

a year ago

Top Midday Gainers

TRVI

MT Newswires

a year ago

Sector Update: Health Care

Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday?
TRVI

Benzinga

a year ago

Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday?

TRVI

MT Newswires

a year ago

Trevi Therapeutics Reaches 75% of Enrollment Target for Phase 2B IPF Chronic Cough Study

Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough
TRVI

PR Newswire

a year ago

Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough

Companies Like Trevi Therapeutics (NASDAQ:TRVI) Are In A Position To Invest In Growth
TRVI

Simply Wall St.

a year ago

Companies Like Trevi Therapeutics (NASDAQ:TRVI) Are In A Position To Invest In Growth

TRVI

MT Newswires

a year ago

Trevi Therapeutics Reports Mixed Results for Human Abuse Potential Study of Cough Treatment

Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine
TRVI

PR Newswire

a year ago

Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine

Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
TRVI

PR Newswire

a year ago

Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

TRVI

Thomson Reuters StreetEvents

a year ago

Q3 2024 Trevi Therapeutics Inc Earnings Call

Trevi Therapeutics Inc (TRVI) Q3 2024 Earnings Call Highlights: Navigating Increased Losses and ...
TRVI

GuruFocus.com

a year ago

Trevi Therapeutics Inc (TRVI) Q3 2024 Earnings Call Highlights: Navigating Increased Losses and ...

Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
TRVI

PR Newswire

a year ago

Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024
TRVI

PR Newswire

a year ago

Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024

Rosalind Advisors, Inc. Reduces Stake in Trevi Therapeutics Inc.
TRVI

GuruFocus.com

a year ago

Rosalind Advisors, Inc. Reduces Stake in Trevi Therapeutics Inc.

TRVI

MT Newswires

a year ago

Trevi Therapeutics Completes Enrollment for Phase 2a Trial of Refractory Chronic Cough Treatment; Shares Rise

Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough
TRVI

PR Newswire

a year ago

Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough

Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences
TRVI

PR Newswire

a year ago

Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences

Trevi Therapeutics Inc (TRVI) Q2 2024 Earnings Call Highlights: Navigating Financial Challenges ...
TRVI

GuruFocus.com

a year ago

Trevi Therapeutics Inc (TRVI) Q2 2024 Earnings Call Highlights: Navigating Financial Challenges ...

Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program
TRVI

PR Newswire

a year ago

Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program

TRVI

MT Newswires

a year ago

Trevi Therapeutics Appoints Chief Development Officer

Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer
TRVI

PR Newswire

a year ago

Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer

Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024
TRVI

PR Newswire

a year ago

Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024

Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024
TRVI

PR Newswire

a year ago

Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024

Abercrombie upgraded, Dollar General downgraded: Wall Street's top analyst calls
TRVI

The Fly

a year ago

Abercrombie upgraded, Dollar General downgraded: Wall Street's top analyst calls

TRVI

MT Newswires

a year ago

Raymond James Starts Trevi Therapeutics With Outperform Rating

TRVI

MT Newswires

a year ago

HC Wainwright Initiates Trevi Therapeutics at Buy

Trevi Therapeutics to Participate in September Investor and Medical Conferences
TRVI

PR Newswire

a year ago

Trevi Therapeutics to Participate in September Investor and Medical Conferences

Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance
TRVI

PR Newswire

a year ago

Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance

Institutional investors in Trevi Therapeutics, Inc. (NASDAQ:TRVI) see US$40m decrease in market cap last week, although long-term gains have benefitted them.
TRVI

Simply Wall St.

a year ago

Institutional investors in Trevi Therapeutics, Inc. (NASDAQ:TRVI) see US$40m decrease in market cap last week, although long-term gains have benefitted them.

Trevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024
TRVI

PR Newswire

a year ago

Trevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024

Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events
TRVI

PR Newswire

a year ago

Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events

Here's Why We're Not Too Worried About Trevi Therapeutics' (NASDAQ:TRVI) Cash Burn Situation
TRVI

Simply Wall St.

a year ago

Here's Why We're Not Too Worried About Trevi Therapeutics' (NASDAQ:TRVI) Cash Burn Situation

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2024 Earnings Call Transcript
TRVI

Insider Monkey

2 years ago

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2024 Earnings Call Transcript

Trevi Therapeutics to Participate in Upcoming Conferences
TRVI

PR Newswire

2 years ago

Trevi Therapeutics to Participate in Upcoming Conferences

TRVI

Thomson Reuters StreetEvents

2 years ago

Q1 2024 Trevi Therapeutics Inc Earnings Call

TRVI

GuruFocus.com

2 years ago

Trevi Therapeutics Reports Q1 2024 Financial Results: A Detailed Analysis

Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
TRVI

PR Newswire

2 years ago

Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024
TRVI

PR Newswire

2 years ago

Trevi Therapeutics to Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 7, 2024

Trevi Therapeutics (TRVI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
TRVI

Zacks

2 years ago

Trevi Therapeutics (TRVI) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference
TRVI

PR Newswire

2 years ago

Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference

Why Trevi Therapeutics (TRVI) Stock Might be a Great Pick
TRVI

Zacks

2 years ago

Why Trevi Therapeutics (TRVI) Stock Might be a Great Pick

Trevi Therapeutics to Participate in Upcoming April Events
TRVI

PR Newswire

2 years ago

Trevi Therapeutics to Participate in Upcoming April Events

Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team
TRVI

PR Newswire

2 years ago

Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2023 Earnings Call Transcript
TRVI

Insider Monkey

2 years ago

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2023 Earnings Call Transcript

TRVI

GuruFocus.com

2 years ago

Trevi Therapeutics Inc (TRVI) Announces Year-End Financials and Progress in Clinical Trials

Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates
TRVI

PR Newswire

2 years ago

Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates

Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024
TRVI

PR Newswire

2 years ago

Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024

private equity firms who own 35% along with institutions invested in Trevi Therapeutics, Inc. (NASDAQ:TRVI) saw increase in their holdings value last week
TRVI

Simply Wall St.

2 years ago

private equity firms who own 35% along with institutions invested in Trevi Therapeutics, Inc. (NASDAQ:TRVI) saw increase in their holdings value last week

Trevi Therapeutics to Participate in Upcoming March Events
TRVI

PR Newswire

2 years ago

Trevi Therapeutics to Participate in Upcoming March Events

Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
TRVI

PR Newswire

2 years ago

Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Fisker Welcomes Dealers From Across North America to Its First Open House and Signs First US Dealer Partner
TRVI

Business Wire

2 years ago

Fisker Welcomes Dealers From Across North America to Its First Open House and Signs First US Dealer Partner

Planet Image International Limited Announces Closing of $5 Million Initial Public Offering
TRVI

PR Newswire

2 years ago

Planet Image International Limited Announces Closing of $5 Million Initial Public Offering

Chemung Financial Corporation (NASDAQ:CHMG) Analysts Are Pretty Bullish On The Stock After Recent Results
TRVI

Simply Wall St.

2 years ago

Chemung Financial Corporation (NASDAQ:CHMG) Analysts Are Pretty Bullish On The Stock After Recent Results

Share on Social Networks: